title: Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy.
abstract: Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.
authors.affiliation: Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
authors.forename: James L
authors.initials: JL
authors.lastname: Reading
authors.affiliation: Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Quezada
mesh_terms: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D061026:Programmed Cell Death 1 Receptor